Induction immunosuppression for orthotopic heart transplantation: A review

Progress in Transplantation

Volumn 19, Issue 4, 2009, Pages 333-341

  Ensor, Christopher R ^a   Cahoon, William D ^b   Hess, Michael L ^b   Kasirajan, Vigneshwar ^b   Cooke, Richard H ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861556048     PISSN: 15269248     EISSN: None     Source Type: Journal    
DOI: 10.1177/152692480901900408     Document Type: Article

References (45)

1. Denton MD, Magee CC, Seyegh MH. Immunosuppressive strategies in transplantation. Lancet. 1999;353:1083-1091 (Pubitemid 29149926)
2. Higgins R, Kirklin JK, Brown RN, et al. To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy. J Heart Lung Transplant. 2005;24(4):392-400 (Pubitemid 40403793)
3. Uber P, Mehra M. Induction therapy in heart transplantation: is there a role. J Heart Lung Transplant. 2007;26:205-209 (Pubitemid 46341883)
4. Lindenfeld J, Miller G, Shakar S, et al. Drug therapy in the heart transplant recipient: part 1: cardiac rejection and immunosuppressive drugs. Circulation. 2004;110:3734-3740 (Pubitemid 39665265)
5. Hershberger R, Starling R, Eisen H, et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med. 2005;352:2705-2713 (Pubitemid 41007825)
6. Ortiz V, Almenar L, Martinez-Dolz L, et al. Induction therapy with daclizumab in heart transplantation-how many doses. Transplant Proc. 2006;38:2541-2543 (Pubitemid 44693682)
7. Cohen O, Zerda D, Beygui R, Hekmat D, Laks H. Ethnicity as a predictor of graft longevity and recipient mortality in heart transplantation. Transplant Proc. 2007;39:3297-3302 (Pubitemid 350251467)
8. Al Aly Z, Abbas S, Moore E, Daillo O, Hauptman P, Bastani B. The natural history of renal function following orthotopic heart transplant. Clin Transplant. 2005;19:683-689 (Pubitemid 41341702)
9. Odim J, Wheat J Laks H, et al. Peri-operative renal function and outcome after orthotopic heart transplantation. J Heart Lung Transplant. 2006;25:162-166 (Pubitemid 43156366)
10. Rosenberg P, Vriesendorp A, Drazner M, et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant. 2005;24:1327-1331 (Pubitemid 41247817)
11. Delgato D, Miriuka S, Cusimano R, Feindel C, Rao V, Ross H. Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction. J Heart Lung Transplant. 2005;14:166-169 (Pubitemid 40215592)
12. Bonnefoy-Bernard N, Revillard J. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant. 1996;15:435-442 (Pubitemid 26171239)
13. Bourdage J, Hamlin D. Comparative polyclonal antithymocyte globulin and antilymphocyte.amtilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation. 1995;59:1194-1200
14. Genzyme. Thymoglobulin package insert. Cambridge, MA. 2007. http://www.thymoglobulin.com/home/thymo-pdf-pi.pdf. Accessed May 3, 2009
15. Ortho-Biotech. Orthoclone OKT3 package insert. Raritan, NJ. 2001. http://www.orthobiotech.com/orthobiotech/shared/OBI/PI/OKT3-PI.pdf. Accessed May 3, 2009
16. Caillat-Zucman S, Blumenfeld N, Legendre C, et al. The OKT3 immunosuppressive effect. Transplant. 1990;49:156-160
17. Hammond E, Wittwer C, Greenwood J, et al. Relationship of OKT3 sensitization and vascular rejection in cardiac transplant patients receiving OKT3 rejection prophylaxis. Transplantation. 1990;50:776-782
18. Haddad M, Alghofaili F, Fergusson D, Masters R. Induction immunosuppression after heart transplantation: monoclonal vs. polyclonal antithymoglobulins. Is there a difference? Inter Cardiovasc Thorac Surg. 2005;4:415-9 (Pubitemid 43093598)
19. Zhang R, Haverich A, Struber M, Simon A, Bara C. Delayed onset of cardiac allograft vasculopathy by induction therapy using antithymocyte globulin. J Heart Lung Transplant. 2008; 27:603-609 (Pubitemid 351711706)
20. Hauptman P, Mehra R. Its time to stop ignoring malignancy in heart transplantation: a call to arms. J Heart Lung Transplant. 2005;24:166-169
21. Ippoliti G, Rinaldi M, Pellegrini C, Vigano M. Incidence of cancer after immunosuppressive treatment for heart transplantation. Crit Rev Oncol Hematol. 2005;56:101-113 (Pubitemid 41278649)
22. Swinnen L, Costanzo-Nordin M, Fisher S, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiactransplant recipients. N Engl J Med. 1990;323:1723-1728
23. El-Hamamsy I, Stevens L, Carrier M, et al. Incidence and prognosis of cancer following heart transplantation using rATG induction therapy. Transplant Int. 2005;18:1280-1285 (Pubitemid 41726749)
24. Sagedal S, Hartmann A, Nordal K, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int. 2004;66:329-337 (Pubitemid 38870110)
25. San-Juan R, Aguado K, Lumberas C, et al. Impact of current transplantation management on the development of cytomega - lovirus disease after renal transplant. CID. 2008;47:875-882
26. Syndman D. Persistent clinical impact of cytomegalovirus in organ transplantation. CID. 2008;47:883-884
27. Mattei M, Redonnet M, Gandjbakhch I, et al. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus antithymocyte globulin as induction therapy. JHeart Lung Transplant. 2007;26:693-699 (Pubitemid 47001715)
28. Taylor D, Edwards L, Boucek M, et al. Registry of the international society for heart and lung transplantation: twenty-fourth official adult heart transplant report-2007. J Heart Lung Transplant. 2007;26:769-781 (Pubitemid 47199081)
29. Moller C, Gustafsson F, Gluud C, Steinbruchel D. Interleukin- 2 receptor antiagonists as induction therapy after heart transplantation: systematic review with meta-analysis of randomized trails. J Heart Lung Transplant. 2008;27:835-842
30. Beniaminovitz A, Itescu S, Lietz K, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin- 2 receptor with a monoclonal antibody. N Engl J Med. 2000; 342:613-619 (Pubitemid 30118413)
31. ter Meulen C, Baan C, Hene R, Hilbrands L, Hoitsma A. Two doses of daclizumab are sufficient for prolonged interleukin- 2Ralpha chain blockade. Transplantation. 1999;67:276-284.
32. Kobashigawa J, Morris D, Chu A, Steffen B, Gotz V, Gordon R. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids. Transplant Proc. 2005; 37:1333-1339 (Pubitemid 40590880)
33. Novartis. Simulect package insert. East Hanover, NJ. 2005. http://www.pharma.us.novartis.com/product/pi/pdf/simulect .pdf. Accessed May 3, 2009
34. Kahan B, Rajagopalan P, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimaric anti-interleukin-2-receptor monoclonal antibody. Transplant. 1999;67:276-284 (Pubitemid 29066355)
35. Hoffmann-La Roche. Zenapax package insert. Nutley, NJ. 2003
36. Stratta R, Alloway R, Lo A, Hodge E. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study. Transplant. 2003;75:1260-1266 (Pubitemid 36513031)
37. Das B, Shoemaker L, Recto M, Austin E, Dowling R. Alemtuzumab induction in a pediatric heart transplant: successful outcome and rationale for its use. J Heart Lung Transplant. 2008;27:242-244 (Pubitemid 351221050)
38. Woodside K, Lick S. Alemtuzumab as successful salvage therapy for recurrent steroid-resistant heart transplant rejection. J Heart Lung Transplant. 2007;26:750-752 (Pubitemid 47001712)
39. Lick S, Vaidya S, Kollar A, Boor P, Vertrees R. Peri-operative alemtuzumab and plasmapheresis for high-PRA positive lymphocyte crossmatch heart transplant: a strategy to shorten left ventricular assist device support. J Heart Lung Transplant. 2008;27:1036-1039
40. Lenihan D, Alencar A, Yang D, Kurzrock R, Keating M, Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/sezary syndrome. Blood. 2004;104:655-658 (Pubitemid 38970557)
41. Basquiera A, Berretta A, Garcia J, Palazzo E. Coronary ischemia related to alemtuzumab therapy. Ann Oncol. 2004;15:539-540 (Pubitemid 38444566)
42. Oshima K, Sakata-Yanagimoto M, Asano-Mori Y, et al. Cardiac complications after haploidentical HLA-mismatched hema - topoietic stem cell transplantation using in vivo alemtuzumab. Bone Marrow Transplant. 2005;36:821-824 (Pubitemid 41613306)
43. Carlsen J, Johansen M, Boesgaard S, et al. Induction therapy after cardiac transplantation: a comparison of antithymocyte globulin and daclizumab in the prevention of acute rejection. J Heart Lung Transplant. 2005;24:296-302 (Pubitemid 40312054)
44. Flaman F, Zieroth S, Rao V, Ross H, Delgado D. Basiliximab versus rabbit antithymocyte globulin for induction therapy in patients after heart transplantation. J Heart Lung Transplant. 2006;25:1358-1362 (Pubitemid 44692505)
45. Carrier M, Leblanc M, Perrault L, et al. Basiliximab and rabbit antithymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial. J Heart Lung Transplant. 2007;26:258-263. (Pubitemid 46341886)